Catechol-O-Methyltransferase and pain

International Review of Neurobiology

Volumn 95, Issue C, 2010, Pages 227-279

  Kambur, Oleg ^a   Männistö, Pekka T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Carrageenan test; Catechol O methyltransferase; COMT; COMT activity; COMT knock out mice; Function of COMT isoforms; Hot plate test; Neuropathic pain; Paw flick; S COMT deficient mice; Spinal nerve ligation; Tail flick

Indexed keywords

2' FLUORO 3,4 DIHYDROXY 5 NITROBENZOPHENONE; 3,5 DINITROPYROCATECHOL; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; GABAPENTIN; MORPHINE; N (6 OXO 1H PYRID 2 YL) N',N' DIPROPYLFORMAMIDINE; NARCOTIC ANALGESIC AGENT; NITECAPONE; TOLCAPONE;

AMINO ACID SUBSTITUTION; ANALGESIA; ANTIOXIDANT ACTIVITY; BOOK; CANCER PAIN; CHRONIC PAIN; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME POLYMORPHISM; FIBROMYALGIA; GENOTYPE PHENOTYPE CORRELATION; HEADACHE; HOT PLATE TEST; HUMAN; KNOCKOUT MOUSE; MIGRAINE; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TAIL FLICK TEST; TEMPOROMANDIBULAR JOINT DISORDER;

EID: 78649391460     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381326-8.00010-7     Document Type: Chapter

References (153)

1. Andersen S., Skorpen F. Variation in the COMT gene: implications for pain perception and pain treatment. Pharmacogenomis 2009, 10:669-684.
2. Armero P., Muriel C., Santos J., Sanchez-Montero F.J., Rodriguez R.E., Gonzalez-Sarmiento R. COMT (Val158Met) polymorphism is not associated to neuropathic pain in a Spanish population. Eur. J. Pain 2005, 9:229-232.
3. Baba H., Goldstein P.A., Okamoto M., Kohno T., Ataka T., Yoshimura M., Shimoji K. Noradrenaline facilitates inhibitory transmission in substantia gelatinosa of adult rat spinal cord (part 2): effects on somatodendritic sites of GABAergic neurons. Anesthesiology 2000, 92:485-492.
4. Babovic D., O'Tuathaigh C.M., O'Connor A.M., O'Sullivan G.J., Tighe O., Croke D.T., Karayiorgou M., Gogos J.A., Cotter D., Waddington J.L. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience 2008, 155:1021-1029.
5. Barnett J.H., Jones P.B., Robbins T.W., Muller U. Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin card sort test in schizophrenia and healthy controls. Mol. Psychiatry 2007, 12:502-509.
6. Berthele A., Platzer S., Jochim B., Boecker H., Buettner A., Conrad B., Riemenschneider M., Toelle T.R. COMT Val108/158Met genotype affects the mu-opioid receptor system in the human brain: evidence from ligand-binding, G-protein activation and preproenkephalin mRNA expression. NeuroImage 2005, 28:185-193.
7. Bertolino A., Caforio G., Blasi G., De Candia M., Latorre V., Petruzzella V., Altamura M., Nappi G., Papa S., Callicott J.H., Mattay V.S., Bellomo A., Scarabino T., Weinberger D.R., Nardini M. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry 2004, 161:1798-1805.
8. Birklein F., Depmeier C., Rolke R., Hansen C., Rautenstrauss B., Prawitt D., Magerl W. A family-based investigation of cold pain tolerance. Pain 2008, 138:111-118.
9. Boudikova B., Szumlanski C., Maidak B., Weinshilboum R. Human liver catechol-O-methyltransferase pharmacogenetics. Clin. Pharmacol. Ther. 1990, 48:381-389.
10. Cass W.A., Zahniser N.R., Flach K.A., Gerhardt G.A. Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: role of metabolism and effects of locally applied uptake inhibitors. J. Neurochem. 1993, 61:2269-2278.
11. Cevoli S., Mochi M., Scapoli C., Marzocchi N., Pierangeli G., Pini L.A., Cortelli P., Montagna P. A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur. J. Neurol. 2006, 13:1009-1013.
12. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., Weinberger D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 2004, 75:807-821.
13. Cohen H., Neumann L., Glazer Y., Ebstein R.P., Buskila D. The relationship between a common catechol-O-methyltransferase (COMT) polymorphism val(158) met and fibromyalgia. Clin. Exp. Rheumatol. 2009, 27:S51-S56.
14. Costigan M., Befort K., Karchewski L., Griffin R.S., D'Urso D., Allchorne A., Sitarski J., Mannion J.W., Pratt R.E., Woolf C.J. Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. BMC Neurosci. 2002, 3:16.
15. Costigan M., Scholz J., Woolf C.J. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu. Rev. Neurosci. 2009, 32:1-32.
16. Danzebrink R.M., Gebhart G.F. Antinociceptive effects of intrathecal adrenoceptor agonists in a rat model of visceral nociception. J. Pharmacol. Exp. Ther. 1990, 253:698-705.
17. Davis W.M., Hatoum N.S., Khalsa J.H. Toxic interaction between narcotic analgesics and inhibitors of catechol-O-methyltransferase. Toxicology 1979, 14:217-227.
18. De Kock M., Crochet B., Morimont C., Scholtes J.L. Intravenous or epidural clonidine for intra- and postoperative analgesia. Anesthesiology 1993, 79:525-531.
19. Diatchenko L., Nackley A.G., Slade G.D., Bhalang K., Belfer I., Max M.B., Goldman D., Maixner W. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 2006, 125:216-224.
20. Diatchenko L., Slade G.D., Nackley A.G., Bhalang K., Sigurdsson A., Belfer I., Goldman D., Xu K., Shabalina S.A., Shagin D., Max M.B., Makarov S.S., Maixner W. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum. Mol. Genet. 2005, 14:135-143.
21. Di Chiara G., Tanda G.L., Frau R., Carboni E. Heterologous monoamine reuptake: lack of transmitter specificity of neuron-specific carriers. Neurochem. Int. 1992, 20(Suppl.):231S-235S.
22. Dina O.A., Khasar S.G., Alessandri-Haber N., Bogen O., Chen X., Green P.G., Reichling D.B., Messing R.O., Levine J.D. Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy. Eur. J. Neurosci. 2008, 28:1180-1190.
23. Dina O.A., Khasar S.G., Alessandri-Haber N., Bogen O., Chen X., Green P.G., Reichling D.B., Messing R.O., Levine J.D. Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy. Eur. J. Neurosci. 2009, 30:2235.
24. Djaldetti R., Shifrin A., Rogowski Z., Sprecher E., Melamed E., Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology 2004, 62:2171-2175.
25. Eisenhofer G., Kopin I.J., Goldstein D.S. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 2004, 56:331-349.
26. Evans R.W. Persistent post-traumatic headache, postconcussion syndrome, and whiplash injuries: the evidence for a non-traumatic basis with an historical review. Headache 2010, 50:716-724.
27. Farrar J.T., Young J.P., LaMoreaux L., Werth J.L., Poole R.M. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001, 94:149-158.
28. Fernandes K.J.L., Tetzlaff W. Gene expression in axotomized neurons: identifying the intrinsic determinants of axonal growth. Axonal Regeneration in the Central Nervous System 2001, 219-266. Marcel Dekker, New York. N.A. Ingoglia, M. Murray (Eds.).
29. Fijal B., Perlis R.H., Heinloth A.N., Houston J.P. The association of single nucleotide polymorphisms in the catechol-o-methyltransferase gene and pain scores in female patients with major depressive disorder. J. Pain 2010, 11:910-915.
30. Finan P.H., Zautra A.J., Davis M.C., Lemery-Chalfant K., Covault J., Tennen H. Genetic influences on the dynamics of pain and affect in fibromyalgia. Health Psychol. 2010, 29:134-142.
31. Finnerup N.B., Otto M., McQuay H.J., Jensen T.S., Sindrup S.H. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005, 118:289-305.
32. Gao X., Kim H.K., Chung J.M., Chung K. Enhancement of NMDA receptor phosphorylation of the spinal dorsal horn and nucleus gracilis neurons in neuropathic rats. Pain 2005, 116:62-72.
33. George S.Z., Dover G.C., Wallace M.R., Sack B.K., Herbstman D.M., Aydog E., Fillingim R.B. Biopsychosocial influence on exercise-induced delayed onset muscle soreness at the shoulder: pain catastrophizing and catechol-o-methyltransferase (COMT) diplotype predict pain ratings. Clin. J. Pain 2008, 24:793-801.
34. George S.Z., Wallace M.R., Wright T.W., Moser M.W., Greenfield W.H., Sack B.K., Herbstman D.M., Fillingim R.B. Evidence for a biopsychosocial influence on shoulder pain: pain catastrophizing and catechol-O-methyltransferase (COMT) diplotype predict clinical pain ratings. Pain 2008, 136:53-61.
35. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379:606-612.
36. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:9991-9996.
37. Guldberg H.C., Marsden C.A. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol. Rev. 1975, 27:135-206.
38. Haasio K., Huotari M., Nissinen E., Männist P.T. Tissue histopathology, clinical chemistry and behaviour of adult Comt gene-disrupted mice. J. Appl. Toxicol. 2003, 23:213-219.
39. Hagen K., Pettersen E., Stovner L.J., Skorpen F., Zwart J.A. No association between chronic musculoskeletal complaints and Val158Met polymorphism in the Catechol-O-methyltransferase gene. The HUNT study. BMC Musculoskelet. Disord. 2006, 7:40.
40. Hagen K., Pettersen E., Stovner L.J., Skorpen F., Zwart J.A. The association between headache and Val158Met polymorphism in the catechol-O-methyltransferase gene: the HUNT Study. J. Headache Pain 2006, 7:70-74.
41. Helkamaa T., Reenil I., Tuominen R.K., Soinila S., Väänänen A., Tilgmann C., Rauhala P. Increased catechol-O-methyltransferase activity and protein expression in OX-42-positive cells in the substantia nigra after lipopolysaccharide microinfusion. Neurochem. Int. 2007, 51:412-423.
42. Hocking L.J., Smith B.H., Jones G.T., Reid D.M., Strachan D.P., Macfarlane G.J. Genetic variation in the beta2-adrenergic receptor but not catecholamine-O-methyltransferase predisposes to chronic pain: results from the 1958 British Birth Cohort Study. Pain 2010, 149:143-151.
43. Hökfelt T., Zhang X., Wiesenfeld-Hallin Z. Messenger plasticity in primary sensory neurons following axotomy and its functional implications. Trends Neurosci. 1994, 17:22-30.
44. Hong J., Shu-Leong H., Tao X., Lap-Ping Y. Distribution of catechol-O-methyltransferase expression in human central nervous system. NeuroReport 1998, 9:2861-2864.
45. Huehne K., Leis S., Muenster T., Wehrfritz A., Winter S., Maihofner C., Foertsch T., Croner R., Reis A., Winterpacht A., Rautenstrauss B. High post surgical opioid requirements in Crohn's disease are not due to a general change in pain sensitivity. Eur. J. Pain 2009, 13:1036-1042.
46. Huotari M., Garcia-Horsman J.A., Karayiorgou M., Gogos J.A., Männist P.T. D-amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology (Berl.) 2004, 172:1-10.
47. Huotari M., Gogos J.A., Karayiorgou M., Koponen O., Forsberg M., Raasmaja A., Hyttinen J., Männist P.T. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur. J. Neurosci. 2002, 15:246-256.
48. Huotari M., Santha M., Lucas L.R., Karayiorgou M., Gogos J.A., Männist P.T. Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. J. Pharmacol. Exp. Ther. 2002, 303:1309-1316.
49. Irwin S., Houde R.W., Bennett D.R., Hendershot L.C., Seevers M.H. The effects of morphine methadone and meperidine on some reflex responses of spinal animals to nociceptive stimulation. J. Pharmacol. Exp. Ther. 1951, 101:132-143.
50. Izumi J., Inagaki M., Kiuchi Y., Matsumoto M., Yamazaki Y., Morioka D., Usami S., Oguchi K. Sustained increase in adrenergic activity in gerbil striatum following transient ischemia. Jpn. J. Pharmacol. 1993, 63:143-149.
51. Jacobsen L.M., Eriksen G.S., Pedersen L.M., Gjerstad J. Catechol-O-methyltransferase (COMT) inhibition reduces spinal nociceptive activity. Neurosci. Lett. 2010, 473:212-215.
52. Jakobi J., Bernateck M., Tran A.T., Holm L., Volkmann L., Buers D., Karst M., Stuhrmann M. Catechol-O-methyltransferase gene polymorphisms are not associated with multisomatoform disorder in a group of German multisomatoform disorder patients and healthy controls. Genet. Test. Mol. Biomarkers 2010, 14:293-297.
53. Jensen K.B., Lonsdorf T.B., Schalling M., Kosek E., Ingvar M. Increased sensitivity to thermal pain following a single opiate dose is influenced by the COMT val(158)met polymorphism. PLoS ONE 2009, 4:e6016.
54. Joshi S.K., Hernandez G., Mikusa J.P., Zhu C.Z., Zhong C., Salyers A., Wismer C.T., Chandran P., Decker M.W., Honore P. Comparison of antinociceptive actions of standard analgesics in attenuating capsaicin and nerve-injury-induced mechanical hypersensitivity. Neuroscience 2006, 143:587-596.
55. Kaakkola S., Männist P.T., Nissinen E. Striatal membrane-bound and soluble catechol-O-methyl-transferase after selective neuronal lesions in the rat. J. Neural Transm. 1987, 69:221-228.
56. Käenmäki M., Tammimäki A., Garcia-Horsman J.A., Myöhänen T., Schendzielorz N., Karayiorgou M., Gogos J.A., Männist P.T. Importance of membrane-bound catechol-O-methyltransferase in L-DOPA metabolism: a pharmacokinetic study in two types of Comt gene modified mice. Br. J. Pharmacol. 2009, 158:1884-1894.
57. Käenmäki M., Tammimäki A., Myöhänen T., Pakarinen K., Amberg C., Karayiorgou M., Gogos J.A., Männist P.T. Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J. Neurochem. 2010, 114:1745-1755.
58. Kambur O., Männist P.T., Pusa A.M., Käenmäki M., Kalso E.A., Kontinen V.K. Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats. Eur. J. Pain 2010, in press.
59. Kambur O., Männist P.T., Viljakka K., Reenil I., Lemberg K., Kontinen V.K., Karayiorgou M., Gogos J.A., Kalso E. Stress-induced analgesia and morphine responses are changed in catechol-O-methyltransferase-deficient male mice. Basic Clin. Pharmacol. Toxicology 2008, 103:367-373.
60. Kambur O., Talka R., Ansah O.B., Kontinen V.K., Pertovaara A., Kalso E., Männist P.T. Inhibitors of catechol-O-methyltransferase sensitize mice to pain. Br. J. Pharmacol. 2010, in press.
61. Karhunen T., Tilgmann C., Ulmanen I., Panula P. Catechol-O-methyltransferase (COMT) in rat brain: immunoelectron microscopic study with an antiserum against rat recombinant COMT protein. Neurosci. Lett. 1995, 187:57-60.
62. Karhunen T., Tilgmann C., Ulmanen I., Panula P. Neuronal and non-neuronal catechol-O-methyltransferase in primary cultures of rat brain cells. Int. J. Dev. Neurosci. 1995, 13:825-834.
63. Karhunen T., Ulmanen I., Panula P. Catechol-O-methyltransferase in rat sensory ganglia and spinal cord. Neuroscience 1996, 73:267-276.
64. Khasar S.G., McCarter G., Levine J.D. Epinephrine produces a beta-adrenergic receptor-mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors. J. Neurophysiol. 1999, 81:1104-1112.
65. Kim H., Lee H., Rowan J., Brahim J., Dionne R.A. Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans. Mol. Pain 2006, 2:24.
66. Kim H., Mittal D.P., Iadarola M.J., Dionne R.A. Genetic predictors for acute experimental cold and heat pain sensitivity in humans. J. Med. Genet. 2006, 43:e40.
67. Kim H., Neubert J.K., San Miguel A., Xu K., Krishnaraju R.K., Iadarola M.J., Goldman D., Dionne R.A. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 2004, 109:488-496.
68. Kim H.K., Kim J.H., Gao X., Zhou J.L., Lee I., Chung K., Chung J.M. Analgesic effect of vitamin E is mediated by reducing central sensitization in neuropathic pain. Pain 2006, 122:53-62.
69. Kim H.K., Park S.K., Zhou J.L., Taglialatela G., Chung K., Coggeshall R.E., Chung J.M. Reactive oxygen species (ROS) play an important role in a rat model of neuropathic pain. Pain 2004, 111:116-124.
70. Kim S.H., Chung J.M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992, 50:355-363.
71. Lal M.A., Korner A., Matsuo Y., Zelenin S., Cheng S.X., Jaremko G., DiBona G.F., Eklof A.C., Aperia A. Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. Diabetes 2000, 49:1381-1389.
72. Le Bars D., Dickenson A.H., Besson J.M. Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat. Pain 1979, 6:283-304.
73. Le Bars D., Dickenson A.H., Besson J.M. Diffuse noxious inhibitory controls (DNIC). II. Lack of effect on non-convergent neurones, supraspinal involvement and theoretical implications. Pain 1979, 6:305-327.
74. Leventhal L., Smith V., Hornby G., Andree T.H., Brandt M.R., Rogers K.E. Differential and synergistic effects of selective noradrenaline and serotonin reuptake inhibitors in rodent models of pain. J. Pharmacol. Exp. Ther. 2007, 320:1178-1185.
75. Liang D.Y., Liao G., Wang J., Usuka J., Guo Y., Peltz G., Clark J.D. A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology 2006, 104:1054-1062.
76. Light A.R., White A.T., Hughen R.W., Light K.C. Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. J. Pain 2009, 10:1099-1112.
77. Lipsky R.H., Sparling M.B., Ryan L.M., Xu K., Salazar A.M., Goldman D., Warden D.L. Association of COMT Val158Met genotype with executive functioning following traumatic brain injury. J. Neuropsychiatry Clin. Neurosci. 2005, 17:465-471.
78. Liu Q.S., Qiao J.T., Dafny N. D2 dopamine receptor involvement in spinal dopamine-produced antinociception. Life Sci. 1992, 51:1485-1492.
79. Lötsch J., Fluhr K., Neddermayer T., Doehring A., Geisslinger G. The consequence of concomitantly present functional genetic variants for the identification of functional genotype-phenotype associations in pain. Clin. Pharmacol. Ther. 2009, 85:25-30.
80. Lötsch J., von Hentig N., Freynhagen R., Griessinger N., Zimmermann M., Doehring A., Rohrbacher M., Sittl R., Geisslinger G. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet. Genomics 2009, 19:429-436.
81. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melen K., Julkunen I., Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry (Mosc.) 1995, 34:4202-4210.
82. Lundström K., Salminen M., Jalanko A., Savolainen R., Ulmanen I. Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol. 1991, 10:181-189.
83. Maldonado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci. Biobehav. Rev. 1997, 21:91-104.
84. Männistö P.T., Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 1999, 51:593-628.
85. Männistö P.T., Kaakkola S., Nissinen E., Lindén I.B., Pohto P. Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci. 1988, 43:1465-1471.
86. Männistö P.T., Tuomainen P. Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat. Naunyn. Schmiedebergs Arch. Pharmacol. 1991, 344:412-418.
87. Männistö P.T., Tuomainen P., Tuominen R.K. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br. J. Pharmacol. 1992, 105:569-574.
88. Männistö P.T., Ulmanen I., Lundström K., Taskinen J., Tenhunen J., Tilgmann C., Kaakkola S. Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog. Drug Res. 1992, 39:291-350.
89. Marcocciö L., Maguire J.J., Packer L. Nitecapone: a nitric oxide radical scavenger. Biochem. Mol. Biol. Int. 1994, 34:531-541.
90. Marcocciö L., Suzuki Y.J., Tsuchiya M., Packer L. Antioxidant activity of nitecapone and its analog OR-1246: effect of structural modification on antioxidant action. Methods Enzymol. 1994, 234:526-541.
91. Matsumoto M., Weickert C.S., Akil M., Lipska B.K., Hyde T.M., Herman M.M., Kleinman J.E., Weinberger D.R. Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience 2003, 116:127-137.
92. Max M.B., Wu T., Atlas S.J., Edwards R.R., Haythornthwaite J.A., Bollettino A.F., Hipp H.S., McKnight C.D., Osman I.A., Crawford E.N., Pao M., Nejim J., Kingman A., Aisen D.C., Scully M.A., Keller R.B., Goldman D., Belfer I. A clinical genetic method to identify mechanisms by which pain causes depression and anxiety. Mol. Pain 2006, 2:14.
93. Maze M., Tranquilli W. Alpha-2 adrenoceptor agonists: defining the role in clinical anesthesia. Anesthesiology 1991, 74:581-605.
94. Mazei M.S., Pluto C.P., Kirkbride B., Pehek E.A. Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res. 2002, 936:58-67.
95. Mellon R.D., Bayer B.M. Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action. J. Neuroimmunol. 1998, 83:19-28.
96. Moron J.A., Brockington A., Wise R.A., Rocha B.A., Hope B.T. Dopamine uptake through the noradrenaline transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J. Neurosci. 2002, 22:389-395.
97. Munafo M.R., Bowes L., Clark T.G., Flint J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. Mol. Psychiatry 2005, 10:765-770.
98. Mundorf M.L., Joseph J.D., Austin C.M., Caron M.G., Wightman R.M. Catecholamine release and uptake in the mouse prefrontal cortex. J. Neurochem. 2001, 79:130-142.
99. Munro G. Dopamine D(1) and D(2) receptor agonism enhances antinociception mediated by the serotonin and noradrenaline reuptake inhibitor duloxetine in the rat formalin test. Eur. J. Pharmacol. 2007, 575:66-74.
100. Mylius V., Moller J.C., Strauch K., Oertel W.H., Stiasny-Kolster K. No significance of the COMT val158met polymorphism in restless legs syndrome. Neurosci. Lett. 2010, 473:151-154.
101. Nackley A.G., Diatchenko L. Assessing potential functionality of catechol-O-methyltransferase (COMT) polymorphisms associated with pain sensitivity and temporomandibular joint disorders. Methods Mol. Biol. 2010, 617:375-393.
102. Nackley A.G., Shabalina S.A., Tchivileva I.E., Satterfield K., Korchynskyi O., Makarov S.S., Maixner W., Diatchenko L. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006, 314:1930-1933.
103. Nackley A.G., Tan K.S., Fecho K., Flood P., Diatchenko L., Maixner W. Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta(2)- and beta(3)-adrenergic receptors. Pain 2007, 128:199-208.
104. Narita M., Funada M., Suzuki T. Regulations of opioid dependence by opioid receptor types. Pharmacol. Ther. 2001, 89:1-15.
105. Nicholson R., Dixon A.K., Spanswick D., Lee K. Noradrenergic receptor mRNA expression in adult rat superficial dorsal horn and dorsal root ganglion neurons. Neurosci. Lett. 2005, 380:316-321.
106. Nikoshkov A., Drakenberg K., Wang X., Horvath M.C., Keller E., Hurd Y.L. Opioid neuropeptide genotypes in relation to heroin abuse: dopamine tone contributes to reversed mesolimbic proenkephalin expression. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:786-791.
107. Nissinen E., Lindén I.B., Pohto P. Antioxidant properties of nitecapone are potentiated by glutathione. Biochem. Mol. Biol. Int. 1995, 35:387-395.
108. Nissinen E., Lindén I.B., Schultz E., Kaakkola S., Männist P.T., Pohto P. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur. J. Pharmacol. 1988, 153:263-269.
109. North R.A., Yoshimura M. The actions of noradrenaline on neurones of the rat substantia gelatinosa in vitro. J. Physiol. 1984, 349:43-55.
110. Papaleo F., Crawley J.N., Song J., Lipska B.K., Pickel J., Weinberger D.R., Chen J. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J. Neurosci. 2008, 28:8709-8723.
111. Park J.W., Lee K.S., Kim J.S., Kim Y.I., Shin H.E. Genetic contribution of catechol-o-methyltransferase polymorphism in patients with migraine without aura. J. Clin. Neurol. 2007, 3:24-30.
112. Pedersen L.H., Nielsen A.N., Blackburn-Munro G. Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. Psychopharmacology (Berl.) 2005, 182:551-561.
113. Pertovaara A., Wei H., Kalmari J., Ruotsalainen M. Pain behavior and response properties of spinal dorsal horn neurons following experimental diabetic neuropathy in the rat: modulation by nitecapone, a COMT inhibitor with antioxidant properties. Exp. Neurol. 2001, 167:425-434.
114. Potvin S., Larouche A., Normand E., de Souza J.B., Gaumond I., Grignon S., Marchand S. DRD3 Ser9Gly polymorphism is related to thermal pain perception and modulation in chronic widespread pain patients and healthy controls. J. Pain 2009, 10:969-975.
115. Rakvåg T.T., Klepstad P., Baar C., Kvam T.M., Dale O., Kaasa S., Krokan H.E., Skorpen F. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005, 116:73-78.
116. Rakvåg T.T., Ross J.R., Sato H., Skorpen F., Kaasa S., Klepstad P. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol. Pain 2008, 4:64.
117. Reddy S.V., Yaksh T.L. Spinal noradrenergic terminal system mediates antinociception. Brain Res. 1980, 189:391-401.
118. Redell J.B., Dash P.K. Traumatic brain injury stimulates hippocampal catechol-O-methyl transferase expression in microglia. Neurosci. Lett. 2007, 413:36-41.
119. Reenilä I., Tuomainen P., Soinila S., Männist P.T. Increase of catechol-O-methyltransferase activity in rat brain microglia after intrastriatal infusion of fluorocitrate, a glial toxin. Neurosci. Lett. 1997, 230:155-158.
120. Reyes-Gibby C.C., Shete S., Rakvåg T., Bhat S.V., Skorpen F., Bruera E., Kaasa S., Klepstad P. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007, 130:25-30.
121. Rivett A.J., Francis A., Roth J.A. Distinct cellular localization of membrane-bound and soluble forms of catechol-O-methyltransferase in brain. J. Neurochem. 1983, 40:215-219.
122. Ross J.R., Riley J., Taegetmeyer A.B., Sato H., Gretton S., du Bois R.M., Welsh K.I. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer 2008, 112:1390-1403.
123. Salminen M., Lundström K., Tilgmann C., Savolainen R., Kalkkinen N., Ulmanen I. Molecular cloning and characterization of rat liver catechol-O-methyltransferase. Gene 1990, 93:241-247.
124. Salvemini D., Wang Z.Q., Zweier J.L., Samouilov A., Macarthur H., Misko T.P., Currie M.G., Cuzzocrea S., Sikorski J.A., Riley D.P. A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. Science 1999, 286:304-306.
125. Sand P.G., Korte G., Domani M., Konstandin N., Karl A., Wagner K., Dinnbier M. Alternatively spliced human catechol-O-methyltransferase (COMT) rationalizes lack of Val158Met effects on pain tolerance. Pain 2008, 136:445-446. author reply 446-447.
126. Scher A.I., Gudmundsson L.S., Sigurdsson S., Ghambaryan A., Aspelund T., Eiriksdottir G., van Buchem M.A., Gudnason V., Launer L.J. Migraine headache in middle age and late-life brain infarcts. J. Am. Med. Assoc. 2009, 301:2563-2570.
127. Scherder E., Wolters E., Polman C., Sergeant J., Swaab D. Pain in Parkinson's disease and multiple sclerosis: its relation to the medial and lateral pain systems. Neurosci. Biobehav. Rev. 2005, 29:1047-1056.
128. Sesack S.R., Hawrylak V.A., Matus C., Guido M.A., Levey A.I. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J. Neurosci. 1998, 18:2697-2708.
129. Sindrup S.H., Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999, 83:389-400.
130. Slade G.D., Diatchenko L., Bhalang K., Sigurdsson A., Fillingim R.B., Belfer I., Max M.B., Goldman D., Maixner W. Influence of psychological factors on risk of temporomandibular disorders. J. Dent. Res. 2007, 86:1120-1125.
131. Solomon S. Chronic post-traumatic neck and head pain. Headache 2005, 45:53-67.
132. Stamm S., Riethoven J.J., Le Texier V., Gopalakrishnan C., Kumanduri V., Tang Y., Barbosa-Morais N.L., Thanaraj T.A. ASD: a bioinformatics resource on alternative splicing. Nucleic Acids Res. 2006, 34:D46-D55.
133. Starr C.J., Sawaki L., Wittenberg G.F., Burdette J.H., Oshiro Y., Quevedo A.S., Coghill R.C. Roles of the insular cortex in the modulation of pain: insights from brain lesions. J. Neurosci. 2009, 29:2684-2694.
134. Suzuki Y.J., Tsuchiya M., Safadi A., Kagan V.E., Packer L. Antioxidant properties of nitecapone (OR-462). Free Radic. Biol. Med. 1992, 13:517-525.
135. Tal M. A novel antioxidant alleviates heat hyperalgesia in rats with an experimental painful peripheral neuropathy. NeuroReport 1996, 7:1382-1384.
136. Tammimäki A., Käenmäki M., Kambur O., Kulesskaya N., Keisala T., Karvonen E., Garcia-Horsman J.A., Rauvala H., Männist P.T. Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice. Psychopharmacology (Berl.) 2010, 211:389-401.
137. Tanda G., Pontieri F.E., Frau R., Di Chiara G. Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine. Eur. J. Neurosci. 1997, 9:2077-2085.
138. Tchivileva I.E., Lim P.F., Smith S.B., Slade G.D., Diatchenko L., McLean S.A., Maixner W. Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenet. Genomics 2010, 20:239-248.
139. Tenorio-Laranga J., Männist P.T., Karayiorgou M., Gogos J.A., Garcia-Horsman J.A. Sex-dependent compensated oxidative stress in the mouse liver upon deletion of catechol O-methyltransferase. Biochem. Pharmacol. 2009, 77:1541-1552.
140. Tinazzi M., Del Vesco C., Defazio G., Fincati E., Smania N., Moretto G., Fiaschi A., Le Pera D., Valeriani M. Abnormal processing of the nociceptive input in Parkinson's disease: a study with CO2 laser evoked potentials. Pain 2008, 136:117-124.
141. Tokuyama S., Wakabayashi H., Hoskins B., Ho I.K. Naloxone-precipitated changes in biogenic amines and their metabolites in various brain regions of butorphanol-dependent rats. Pharmacol. Biochem. Behav. 1996, 54:461-468.
142. Trendelenburg U. The interaction of transport mechanisms and intracellular enzymes in metabolizing systems. J. Neural Transm. Suppl. 1990, 32:3-18.
143. Tunbridge E.M., Harrison P.J., Weinberger D.R. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol. Psychiatry 2006, 60:141-151.
144. Urban M.O., Ren K., Park K.T., Campbell B., Anker N., Stearns B., Aiyar J., Belley M., Cohen C., Bristow L. Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. J. Pharmacol. Exp. Ther. 2005, 313:1209-1216.
145. Vargas-Alarcon G., Fragoso J.M., Cruz-Robles D., Vargas A., Lao-Villadoniga J.I., Garcia-Fructuoso F., Ramos-Kuri M., Hernandez F., Springall R., Bojalil R., Vallejo M., Martinez-Lavin M. Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia. Arthritis Res. Ther. 2007, 9:R110.
146. Wang Z.Q., Porreca F., Cuzzocrea S., Galen K., Lightfoot R., Masini E., Muscoli C., Mollace V., Ndengele M., Ischiropoulos H., Salvemini D. A newly identified role for superoxide in inflammatory pain. J. Pharmacol. Exp. Ther. 2004, 309:869-878.
147. Weinshilboum R.M., Raymond F.A. Inheritance of low erythrocyte catechol-o-methyltransferase activity in man. Am. J. Hum. Genet. 1977, 29:125-135.
148. Wilson V.G., Grohmann M., Trendelenburg U. The uptake and O-methylation of 3H-(+/-)-isoprenaline in rat cerebral cortex slices. Naunyn. Schmiedebergs Arch. Pharmacol. 1988, 337:397-405.
149. Wisden W., Herb A., Wieland H., Keinanen K., Luddens H., Seeburg P.H. Cloning, pharmacological characteristics and expression pattern of the rat GABAA receptor alpha 4 subunit. FEBS Lett. 1991, 289:227-230.
150. Yamamoto B.K., Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J. Neurochem. 1998, 71:274-280.
151. Yavich L., Forsberg M.M., Karayiorgou M., Gogos J.A., Männist P.T. Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J. Neurosci. 2007, 27:10196-10209.
152. Zimmermann M. Pathobiology of neuropathic pain. Eur. J. Pharmacol. 2001, 429:23-37.
153. Zubieta J.K., Heitzeg M.M., Smith Y.R., Bueller J.A., Xu K., Xu Y., Koeppe R.A., Stohler C.S., Goldman D. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003, 299:1240-1243.